Jiahao Su*, Meiqin Cai*, Wensheng Li*, Bo Hou†, Haiyong He†, Cong Ling†,Tengchao Huang†, Huijiao Liu†, Ying Guo*
Oncology Research, Vol.24, No.2, pp. 117-128, 2016, DOI:10.3727/096504016X14612603423511
Abstract Glioblastoma (GBM) is the most common primary malignant brain tumor that nearly always results in a bad prognosis. Temozolomide plus radiotherapy (TEM+RAD) is the most common treatment for newly diagnosed GBM.
With the development of molecularly targeted drugs, several clinical trials were reported; however, the efficacy
of the treatment remains controversial. So we attempted to measure the dose of the molecularly targeted drug
that could improve the prognosis of those patients. The appropriate electronic databases (PubMed, MEDLINE,
EMBASE, and the Cochrane Library) were searched for relevant studies. A meta-analysis was performed after
determining which studies… More >
Login
Register
